Extensive deep vein thrombosis as a complication of testicular cancer treated with the BEP protocol (bleomycin, etoposide and cisplatin)
case report
Keywords:
Venous thrombosis, Testicular neoplasms, Chemotherapy, Thrombolytic agents, Pulmonary embolismAbstract
CONTEXT: There are no reports in the literature of massive deep venous thrombosis (DVT) asso- ciated with cisplatin, bleomycin and etoposide (BEP) cancer treatment. CASE REPORT: The patient was a 18 year old adolescent with a nonseminomatous germ cell tumor of the right testicle, with the presence of pulmonary, liver, and massive retroperitoneal metastases. Following radical orchiectomy, the patient started chemotherapy according to the BEP protocol (without routine prophylaxis for DVT). On day 4 of the first cycle, massive DVT was diagnosed, extending from both popliteal veins up to the thoracic segment of the inferior vena cava. Thrombolytic therapy with streptokinase was immediately started. On day 2 of thrombolytic therapy, the patient developed acute renal failure, due to extension of the thrombosis to the renal veins. Streptokinase was continued for six days and the outcome was remarkably favorable.
Downloads
References
Doll DC, Yarbro JW. Vascular toxicity associated with antineo- plastic agents. Semin Oncol. 1992;19(5):580-96.
Letai A, Kuter DJ. Cancer, coagulation, and anticoagulation. Oncologist. 1999;4(6):443-9.
Sugden EM, Griffiths CL, Greywoode GI, Lewis SM. Acute abdomen during adjuvant chemotherapy: superior mesenteric artery thrombosis associated with CMF chemotherapy. Clin Oncol (R Coll Radiol). 2001;13(6):441-3.
Lepidini G, Biancari F, D’Andrea V. Severe thrombosis after chemotherapy for metastatic choriocarcinoma of the testis maintaining complete remission for a long period. Scand J Urol Nephrol. 1997;31(2):221-2.
Icli F, Karaoguz H, Dincol D, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993;72(2):587-93.
Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. 1995;31A(13-14):2229-38.
Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160(6 Pt 1):2021-4.
Gerl A. Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs. 1994;5(6):607-14.
Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 1988;9(5):552-6.
Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemo- therapy. Cancer Chemother Pharmacol. 1987;19(3):253-6.
Cantwell BM, Mannix KA, Roberts JT, Ghani SE, Harris AL. Thromboembolic events during combination chemotherapy for germ cell-malignancy. Lancet. 1988;2(8619):1086-7.
Hall MR, Richards MA, Harper PG. Thromboembolic events during combination chemotherapy for germ cell malignancy. Lancet. 1988;2(8622):1259.
Lederman GS, Garnick MB. Pulmonary emboli as a complication of germ cell cancer treatment. J Urol. 1987;137(6):1236-7.
Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol. 1986;4(9):1405-17.
Stockler M, Raghavan D. Neoplastic venous involvement and pulmonary embolism in patients with germ cell tumors. Cancer. 1991;68(12):2633-6.
Oberhoff C, Winkler UH, Tauchert AM, Schindler AE. Adjuvante CMF-Chemotherapie bei Patientinnen mit Mammakarzinom--Auswirkungen auf Blutgerinnung und Fibrinolyse. [Adjuvant CMF chemotherapy in patients with breast cancer--results on blood coagulation and fibrinolysis]. Zentralbl Gynakol. 1997;119(5):211-7.
Taher A, Shamsseddine A, Saghir N, et al. Acquired protein C deficiency following cisplatinum-navelbine administration for locally advanced breast cancer. Case report. Eur J Gynaecol Oncol. 1999;20(4)323-4.
Vos AH, Splinter TA, van der Heul C. Arterial occlusive events during chemotherapy for germ cell cancer. Neth J Med. 2001;59(6):295-9.
Bachmeyer C, Joly H, Jorest R. Early myocardial infarction during chemotherapy for testicular cancer. Tumori. 2000;86(5):428-30.
Schmidt J, Zenut M, De Marquilly F, Maciejewski C, Plagne R, Lavarenne J. Thrombose artérielle chez un patient traité par chimio- thérapie (Protocole BEP) pour un dysgerminome extra-gonadique. [Arterial thrombosis in a patient after chemotherapy (BEP protocol) for extra-gonadal dysgerminoma]. Therapie. 1995;50(5):476-8.
Yamada K, Yamashiro S, Itoyama Y, Goto S, Uemura S, Ushio Y. [Sinus thrombosis during CDDP and VP-16 (PE) therapy for suprasellar germ-cell tumor: case report]. No Shinkei Geka. 1993;21(11):1025-9.
Strumberg D, Brügge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemo- therapy for non-seminomatous testicular cancer. Ann Oncol. 2002;13(2):229-36.
Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000;18(10):2169-78.
Shlebak AA, Smith DB. Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and/or hormonal therapy. Cancer Chemother Pharmacol. 1997;39(5):462-6.
Dhami MS, Bona RD. Thrombosis in patients with cancer. Postgrad Med. 1993;93(8):131-3, 137-40.
Marder VJ. Thrombolytic therapy: overview of results in major vascular occlusions. Thromb Haemost. 1995;74(1):101-5.
Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin- based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105(1):48-51.
Orlando L, Colleoni M, Nole F, et al. Incidence of venous thromboembolism in breast cancer patients during chemo- therapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required? Ann Oncol. 2000;11(1):117-8.
Ng CM, Rivera JO. Meta-analysis of streptokinase and heparin in deep vein thrombosis. Am J Health Syst Pharm. 1998;55(19):1995-2001.
Gallus AS. Thrombolytic therapy for venous thrombosis and pulmonary embolism. Baillieres Clin Haematol. 1998;11(3):663-73.
Albuquerque LC, Silveira F, Zago AJ, Bettio J, Petracco JB. Terapia trombolítica em trombose venosa profunda. Experi- ência clínica inicial. [Thrombolytic therapy in deep venous thrombosis. Initial clinical experience]. Arq Bras Cardiol. 1997;68(2):125-8.
Weidmann B, Jansen W, Franzen B, Tauchert M. Lysetherapie bei tiefen Beinvenenthrombosen. [Fibrinolytic therapy of deep vein thombosis]. Med Klin (Munich). 1999;94(3):140-9.
Rühlmann C, Engelmann L, Scheel H, Siegemund A, Biesold M. Thrombolyse einer ausgedehnten Venenthrombose der unteren Körperhälfte bei Anomalie der Vena cava inferior. [Thrombolysis of an extensive venous thrombosis of the lower body in an anomaly of the vena cava inferior]. Dtsch Med Wochenschr. 1996;121(5):124-8.
Comerota AJ, Katz ML, White JV. Thrombolytic therapy for acute deep venous thrombosis: how much is enough? Cardiovasc Surg. 1996;4(1):101-4.
Sillesen H, Just S, Jorgensen M, Baekgaard N. Catheter di- rected thrombolysis for treatment of ilio-femoral deep venous thrombosis is durable, preserves venous valve function and may prevent chronic venous insufficiency. Eur J Vasc Endovasc Surg. 2005;30(5):556-62.
Chiou AC, Biggs KL, Matsumura JS. Vena cava filters: why, when, what, how? Perspect Vasc Surg Endovasc Ther. 2005;17(4):329-39.
Koga F, Yamada T, Ishimaru H, Sadaoka SI, Mizuo T. Deep vein thrombosis during chemotherapy in a patient with advanced testicular cancer: successful percutaneous thrombectomy under temporary placement of retrievable inferior vena cava filter. Int J Urol. 2001;8(2):90-3.
Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Throm- bolytic Therapy. Chest. 2004;126(3 Suppl):401S-428S.
